106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2015 All rights reserved
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care.
It focuses on the needs of primary care practice, but also is applicable to providers at all levels. is
Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining
the same results. e ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.
ENDOACR1513
Abbreviations
AIP, aryl hydrocarbon receptor interacting protein; CT, computed tomography; DA,
dopamine agonist; ES, Endocrine Society; FDA, US Food and Drug Administration; GH,
growth hormone; GHRH, growth hormone-releasing hormone; IGF-1, insulin-like growth
factor-1; LAR, long-acting release; MEN1, multiple endocrine neoplasia-1; MRI, magnetic
resonance imaging ; OGTT, oral glucose tolerance test; PO, by mouth; RT, radiotherapy; SRL,
somatostatin receptor ligand; SRT, stereotactic radiotherapy; subcut, subcutaneous
Source
Katznelson L, Laws ER Jr., Murad MH, Melmed S, Molitch ME, Utz A, Wass JAH.
Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab.
2014;30:jc20142700. [Epub ahead of print]
Grading System
Strength of
Recommendation
1 = strong 2 = weak
Quality of Evidence
⊕⊕⊕⊕
= high
⊕⊕⊕
= moderate
⊕⊕
= low
⊕
= very low